10-Q: Sanara MedTech Q3 2025: Strong Surgical Growth, THP Exit

Sanara MedTech reported significant revenue and gross profit growth in its continuing surgical operations for Q3 2025, alongside the strategic discontinuation and impairment of its Tissue Health Plus (THP) segment.

Summary

• Net revenue from continuing operations increased by 22% to $26.3 million for the three months ended September 30, 2025, and by 25% to $75.6 million for the nine months ended September 30, 2025, compared to the prior year periods.
• Gross profit from continuing operations rose by 24% to $24.5 million for the three months and by 28% to $69.9 million for the nine months ended September 30, 2025.
• Net income from continuing operations was $0.8 million for the three months and $0.7 million for the nine months ended September 30, 2025, a significant improvement from net losses in the prior year periods.
• The Tissue Health Plus (THP) segment was discontinued in mid-September 2025 due to persistent losses and lack of investor interest, resulting in a $26.5 million asset impairment charge.
• The discontinuation of THP led to a net loss of $30.4 million for the three months and $36.0 million for the nine months ended September 30, 2025.
• Adjusted EBITDA from continuing operations increased by 91% to $4.9 million for the three months and by 142% to $12.3 million for the nine months ended September 30, 2025.
• Cash on hand decreased to $14.9 million as of September 30, 2025, from $15.9 million at December 31, 2024.
• Total long-term debt increased to $45.1 million as of September 30, 2025, from $30.7 million at December 31, 2024, primarily due to additional borrowings under the CRG Term Loan.
• The company completed the CarePICS Acquisition in April 2025 for $2.0 million cash and assumed $1.65 million in debt, but the acquired technology was fully impaired due to the THP discontinuation.
• Investments in Biomimetic Innovations Limited (BMI) totaled $6.6 million, increasing ownership to approximately 9.678% as of July 1, 2025, and 12.499% as of October 2, 2025, following milestone achievements.

Sentiment

Score: 4

Explanation: While continuing operations show strong revenue growth and a return to profitability, the significant asset impairment charge and the complete write-off of the THP segment, including the CarePICS acquisition, result in a substantial overall net loss and a sharp decline in shareholders' equity. This strategic pivot, while potentially beneficial long-term, introduces considerable short-term financial impact and uncertainty.

Positives

• Net revenue from continuing operations increased by 22% for the three months and 25% for the nine months ended September 30, 2025, driven by increased sales of soft tissue repair and bone fusion products.
• Gross profit from continuing operations grew by 24% for the three months and 28% for the nine months ended September 30, 2025, reflecting strong product demand and lower manufacturing costs for CellerateRX Surgical.
• The company achieved net income from continuing operations of $0.8 million for the three months and $0.7 million for the nine months ended September 30, 2025, a significant turnaround from prior year losses.
• Adjusted EBITDA from continuing operations saw substantial growth, increasing by 91% to $4.9 million for the three months and 142% to $12.3 million for the nine months ended September 30, 2025.
• The company remains in compliance with all debt covenants under the CRG Term Loan Agreement as of September 30, 2025.
• Successful achievement of development, clinical, and regulatory milestones by Biomimetic Innovations Limited (BMI) led to increased equity ownership and expanded exclusive distribution rights for BMI products in the U.S.

Negatives

• The discontinuation of the Tissue Health Plus (THP) segment resulted in a significant net loss from discontinued operations of $31.2 million for the three months and $36.7 million for the nine months ended September 30, 2025.
• An asset impairment charge of $26.5 million was recognized in connection with the disposal of the THP segment, including intangible assets and internal use software, which were written down to zero.
• The overall net loss for the company was $30.4 million for the three months and $36.0 million for the nine months ended September 30, 2025, primarily due to the THP impairment.
• Total shareholders' equity significantly decreased to $6.1 million as of September 30, 2025, from $38.9 million at December 31, 2024, largely due to the accumulated deficit from the THP segment.
• Cash on hand decreased by approximately $0.9 million from December 31, 2024, to September 30, 2025.
• The CarePICS acquisition, completed in April 2025, had its technology fully impaired and earnout liability deemed unattainable due to the discontinuation of the THP segment, rendering the investment valueless.

Risks

• Shortfalls in forecasted revenue growth could impact financial performance.
• Ability to meet future capital requirements, including for potential acquisitions and product development, may be challenging.
• Maintaining compliance with debt obligations, particularly financial covenants, is crucial.
• Challenges in developing and commercializing new products, including manufacturing, distribution, marketing, and sales.
• Difficulty in retaining and recruiting key personnel could hinder operations.
• Intense competition in the markets where the company operates may affect market share and profitability.
• Failure of products to obtain market acceptance could limit revenue generation.
• Security breaches and other disruptions pose risks to data and operations.
• Maintaining effective internal controls over financial reporting is essential for accurate financial reporting.
• Ability to maintain and further grow clinical acceptance and adoption of products is critical for market penetration.
• Competitors inventing superior products could negatively impact market position.
• Disruptions of, or changes in, the distribution model, consumer base, or product supply could affect sales.
• Failure of third-party assessments to demonstrate desired outcomes in proposed endpoints for products under development.
• Ability to protect proprietary rights to technologies and the impact of intellectual property infringement claims.
• Dependence on technologies and products licensed from third parties introduces reliance risks.
• Effects of current and future laws, rules, regulations, and reimbursement policies related to product labeling, marketing, and sales.
• Risk of defects, failures, or quality issues associated with products.

Future Outlook

The company expects to incur $1.5 million to $2.5 million in cash outlays during the last quarter of 2025 related to winding down the Tissue Health Plus (THP) segment, with no material cash spend anticipated after year-end. The company believes its current cash on hand, combined with expected cash flows from operations and $12.25 million available for future borrowing under the CRG Term Loan, will be sufficient to fund organic growth, anticipated operating expenses, and capital expenditures for at least the next 12 months. Future needs for cash include potential acquisitions, further product development, clinical studies, and debt repayment.

Management Comments

• Management initiated a review of strategic options for THP, engaged an investment bank, and ultimately concluded that efforts to find investors or purchasers were unlikely to succeed, leading to the decision to discontinue THP operations.
• Management determined that the technology developed by CarePICS held no value outside of the THP segment following the decision to discontinue THP, leading to its full impairment.
• Management believes Adjusted EBITDA is useful to investors because it facilitates comparisons of core business operations across periods on a consistent basis.

Industry Context

The company operates in the medical technology sector, specifically focusing on the surgical market, including soft tissue repair and bone fusion products, and advanced wound care. The strategic shift to focus solely on the Sanara Surgical segment, following the exit from the Tissue Health Plus (THP) segment, indicates a move towards core profitable areas. The continued expansion of the independent distribution network and investments in innovative products like OsStic and ARC through the BMI partnership suggest a focus on high-growth, specialized areas within the surgical and trauma markets, aligning with broader trends of innovation and cost-effectiveness in healthcare.

Management Changes

Related Party Transactions

• The company has license agreements with Rochal Industries, LLC for BIASURGE Advanced Surgical Solution, CuraShield Antimicrobial Barrier Film, and a debrider product. Ronald T. Nixon (Executive Chairman) and another director are directors and significant shareholders of Rochal.
• A consulting agreement with Ann Beal Salamone, a company director and significant shareholder/Chair of Rochal, provides for an annual fee of $177,697.
• A Transaction Advisory Services Agreement with Catalyst, a related party, incurred costs of $2,338 for the nine months ended September 30, 2025, down from $163,101 in the prior year period.
• Outstanding related party payables totaled $27,339 at September 30, 2025.

Stakeholder Impact

• Shareholders face a significant reduction in total equity due to the THP segment's impairment and discontinuation, impacting per-share book value.
• Employees associated with the THP segment were subject to workforce termination as part of the discontinuation.
• Customers of the Sanara Surgical segment benefit from continued focus and investment in core products and new offerings like BMI's OsStic and ARC.
• Creditors, particularly CRG Term Loan lenders, are impacted by the increased debt load and the strategic shift, though the company remains in compliance with covenants.
• Suppliers to the discontinued THP segment may experience a loss of business, while suppliers to the continuing surgical segment may see stable or increased demand.

Next Steps

• Continue the winding down process for the Tissue Health Plus (THP) segment through the end of 2025, with expected cash outlays of $1.5 million to $2.5 million in Q4 2025.
• Potentially draw down the remaining $12.25 million available under the CRG Term Loan Agreement on or prior to December 31, 2025, subject to conditions.
• Negotiate and finalize terms for additional fields in the BMI License Agreement, with the option period extended through May 31, 2026.
• Continue to develop and commercialize new products based on the exclusive license agreement with Tufts University for collagen peptides.

Key Dates

Recommendation

The company's core surgical business demonstrates strong growth in revenue and gross profit, leading to a return to profitability in continuing operations. This indicates a healthy underlying business. However, the substantial net loss and significant reduction in shareholders' equity due to the discontinuation and impairment of the Tissue Health Plus (THP) segment introduce considerable uncertainty and a one-time negative impact. While the strategic focus on the profitable surgical segment is a positive long-term move, the immediate financial hit and the write-off of recent acquisitions like CarePICS warrant a cautious approach. Investors should monitor the successful integration and commercialization of new products from the BMI partnership and the effective management of the remaining debt obligations, as well as the company's ability to sustain profitability in its streamlined operations.

Keywords

Sanara MedTech, SMTI, medical technology, surgical market, wound care, bone fusion, CellerateRX Surgical, BIASURGE, OsStic, ARC, Biomimetic Innovations Limited, CRG Term Loan, SEC filing, 10-Q, financial results, discontinued operations, Tissue Health Plus, asset impairment, equity investment, CarePICS Acquisition